These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 28135339)
1. Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy. Liu PC; Lu G; Deng Y; Wang CD; Su XW; Zhou JY; Chan TM; Hu X; Poon WS PLoS One; 2017; 12(1):e0171157. PubMed ID: 28135339 [TBL] [Abstract][Full Text] [Related]
2. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB. Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019 [TBL] [Abstract][Full Text] [Related]
3. Combinatorial treatment with anacardic acid followed by TRAIL augments induction of apoptosis in TRAIL resistant cancer cells by the regulation of p53, MAPK and NFκβ pathways. Harsha Raj M; Yashaswini B; Rössler J; Salimath BP Apoptosis; 2016 May; 21(5):578-93. PubMed ID: 26921178 [TBL] [Abstract][Full Text] [Related]
4. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL. Hari Y; Harashima N; Tajima Y; Harada M Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155 [TBL] [Abstract][Full Text] [Related]
6. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway. Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596 [TBL] [Abstract][Full Text] [Related]
7. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells. Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255 [TBL] [Abstract][Full Text] [Related]
8. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway. Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953 [TBL] [Abstract][Full Text] [Related]
9. Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. Chan DY; Chen GG; Poon WS; Liu PC J Neurooncol; 2008 Feb; 86(3):273-83. PubMed ID: 17928957 [TBL] [Abstract][Full Text] [Related]
10. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression. James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742 [TBL] [Abstract][Full Text] [Related]
11. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Jane EP; Premkumar DR; Pollack IF Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502 [TBL] [Abstract][Full Text] [Related]
12. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587 [TBL] [Abstract][Full Text] [Related]
13. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5. Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Ivanov VN; Zhou H; Partridge MA; Hei TK Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839 [TBL] [Abstract][Full Text] [Related]
15. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells. Li L; Wen XZ; Bu ZD; Cheng XJ; Xing XF; Wang XH; Zhang LH; Guo T; Du H; Hu Y; Fan B; Ji JF Oncol Rep; 2016 May; 35(5):3009-17. PubMed ID: 26986870 [TBL] [Abstract][Full Text] [Related]
17. [Study on effect and mechanism of Honokiol enhancing tumor necrosis factor-related apoptosis inducing ligand against hepatocellular carcinoma HepG2 cells via activating JNK signaling pathway]. Xiao G; Yang R; Dang L; Dong CL Zhonghua Gan Zang Bing Za Zhi; 2018 Jun; 26(6):441-445. PubMed ID: 30317758 [No Abstract] [Full Text] [Related]
18. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Moon DO; Kim MO; Choi YH; Kim GY Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942 [TBL] [Abstract][Full Text] [Related]
19. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741 [TBL] [Abstract][Full Text] [Related]
20. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Huerta-Yepez S; Vega M; Escoto-Chavez SE; Murdock B; Sakai T; Baritaki S; Bonavida B Nitric Oxide; 2009 Feb; 20(1):39-52. PubMed ID: 18778787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]